Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors
“Dr. Suliman joins the Ultragenyx Board at a key time for the company, and her corporate and commercial strategy experience will be a valuable asset as we continue to advance our pipeline and deliver therapies to patients with rare diseases in need of treatment options,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx.
“Having watched Ultragenyx over the past few years, the company’s progress in becoming a global, commercial-stage rare disease company has been formidable,” said Dr. Suliman. “I am excited to join the Board and look forward to contributing to the team’s growing success.”
Dr. Suliman has held her current position at Theravance since
About
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the Company's website at www.ultragenyx.com.
Contact
Investors & Media
415-475-6876
Source: Ultragenyx Pharmaceutical Inc.